Evidence map›Paper›PMID 25629161›Full record

ArticlePloS one2015

Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization.

Surender Khurana, Elizabeth M Coyle, Jody Manischewitz, Lisa R King, Glenn Ishioka, Jeff Alexander, Jon Smith, Marc Gurwith, Hana Golding

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01006798 (Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn), which is not on this map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01006798 phase1completednot on this map

Phase 1 Evaluation of the Safety and Immunogenicity of a Replication-Competent Adenovirus Serotype 4-vectored H5N1 Influenza Candidate Vaccine - Ad4-H5-Vtn

TypeinterventionalSponsorEmergent BioSolutionsRan2009 to 2011Enrolled166ConditionsBird Flu, InfluenzaArmsPlacebo, Ad4-H5-Vtn, Sanofi Pasteur Influenza Virus Vaccine, H5N1
3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy.International journal of molecular sciences · 2020
    Review
  7. A Review of DNA Vaccines Against Influenza.Frontiers in immunology · 2018
    Review
  8. Article
  9. Article
  10. Current state and challenges in developing oral vaccines.Advanced drug delivery reviews · 2017
    Review
  11. Future Prospects for the Development of Cost-Effective Adenovirus Vaccines.International journal of molecular sciences · 2017
    Review
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Surender KhuranaDivision of Viral products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, United States of America, 20903.
Elizabeth M CoyleDivision of Viral products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, United States of America, 20903.
Jody ManischewitzDivision of Viral products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, United States of America, 20903.
Lisa R KingDivision of Viral products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, United States of America, 20903.
Glenn IshiokaPaxVax, San Diego, CA, United States of America, 92121.
Jeff AlexanderPaxVax, San Diego, CA, United States of America, 92121.
Jon SmithPaxVax, San Diego, CA, United States of America, 92121.
Marc GurwithPaxVax, Redwood City, CA, United States of America, 94063.
Hana GoldingDivision of Viral products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, United States of America, 20903.
Center for Biologics Evaluation and Research · USPAX Scientific (United States) · USPaxVax (United States) · US

Funding

Wellcome Trust
6 · The paper itself

Abstract

A Phase I trial conducted in 2009-2010 demonstrated that oral vaccination with a replication competent Ad4-H5 (A/Vietnam) vector with dosages ranging from 107-1011 viral particles was well tolerated. HA-specific T-cell responses were efficiently induced, but very limited hemagglutination-inhibiting (HI) humoral responses were measured. However, a single boost of Ad4-H5-Vtn vaccinated individuals with a unadjuvanted licensed H5N1 (A/Vietnam) subunit vaccine resulted in superior HI titers compared with unprimed subjects. In the current study, the impact of Ad4-H5 priming on the quality of the polyclonal humoral immune response was evaluated using a real-time kinetics assay by surface plasmon resonance (SPR). Total binding of serum polyclonal antibodies from the Ad4-H5-Vtn primed groups against both homologous H5N1-A/Vietnam/1194/2004 (clade 1) and heterologous A/Indonesia-5/2005 (clade 2.1) HA1 head domain was significantly higher compared with sera from individuals that received subunit H5N1 vaccination alone. SPR measurements also demonstrated that the antigen-antibody complex dissociation rates (a surrogate for antibody affinity) of serum antibodies against the HA1 of H5N1-A/Vietnam were significantly higher in the Ad4-H5 primed groups compared with those from the unprimed group. Furthermore, strong correlations were observed between the antibody affinities for HA1 (but not HA2) and the virus neutralization titers against the homologous strain and a panel of heterologous clade 2 H5N1 strains. These findings support the concept of oral prime-boost vaccine approaches against pandemic influenza to elicit long-term memory B cells with high affinity capable of rapid response to variant pandemic viruses likely to emerge and adapt to human transmissions.

Indexed as

Adenoviruses, HumanGenetic VectorsImmunization, SecondaryAntibodies, NeutralizingAntibodies, ViralAntibody AffinityClinical Trials, Phase I as TopicCross ReactionsHumansInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesVaccines, SubunitAntibodies, NeutralizingAntibodies, ViralInfluenza VaccinesVaccines, Subunit

Identifiers

PMID25629161
PMCPMC4309450
OpenAlexW1978337075

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.